A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides

NCT07714187 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-07-20

No results posted yet for this study

Summary

This study will evaluate the safety and preliminary efficacy of duvelisib topical gel in participants with early-stage mycosis fungoides.

Conditions

  • Mycosis Fungoides
  • Cutaneous T-cell Lymphoma

Interventions

DRUG

Duvelisib

Topical gel

Sponsors & Collaborators

  • SecuraBio

    lead INDUSTRY

Principal Investigators

  • Reuven Chantre, MD · Secura Bio, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2027-01-31
Primary Completion
2028-10-31
Completion
2029-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07714187 on ClinicalTrials.gov